Gemma Gatta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9173359/publications.pdf Version: 2024-02-01

		7568	6300
225	27,139	77	158
papers	citations	h-index	g-index
231	231	231	31650
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37â€^513â€^025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, The, 2018, 391, 1023-1075.	13.7	3,228
2	Global surveillance of cancer survival 1995–2009: analysis of individual data for 25â€^676â€^887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	13.7	1,863
3	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	10.7	1,554
4	Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncology, The, 2008, 9, 730-756.	10.7	1,059
5	Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncology, The, 2007, 8, 784-796.	10.7	819
6	Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 35-47.	10.7	799
7	EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. European Journal of Cancer, 2009, 45, 931-991.	2.8	740
8	EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology, 2003, 14, v61-v118.	1.2	638
9	Rare cancers are not so rare: The rare cancer burden in Europe. European Journal of Cancer, 2011, 47, 2493-2511.	2.8	573
10	Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. European Journal of Cancer, 2013, 49, 684-695.	2.8	519
11	Survival of European children and young adults with cancer diagnosed 1995–2002. European Journal of Cancer, 2009, 45, 992-1005.	2.8	442
12	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 2003, 14, v128-v149.	1.2	400
13	Major and minor salivary gland tumors. Critical Reviews in Oncology/Hematology, 2010, 74, 134-148.	4.4	387
14	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	2.8	344
15	Incidence of Uveal Melanoma in Europe. Ophthalmology, 2007, 114, 2309-2315.e2.	5.2	327
16	Colon cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 106-133.	4.4	285
17	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncology, The, 2017, 18, 1022-1039.	10.7	285
18	Childhood Cancer Survival Trends in Europe: A EUROCARE Working Group Study. Journal of Clinical Oncology, 2005, 23, 3742-3751.	1.6	276

#	Article	IF	CITATIONS
19	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	2.8	248
20	Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. International Journal of Cancer, 2003, 106, 416-422.	5.1	241
21	Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut, 2000, 47, 533-538.	12.1	234
22	The advantage of women in cancer survival: An analysis of EUROCARE-4 data. European Journal of Cancer, 2009, 45, 1017-1027.	2.8	233
23	Childhood cancer survival in Europe and the United States. Cancer, 2002, 95, 1767-1772.	4.1	231
24	Thymoma and thymic carcinomas. Critical Reviews in Oncology/Hematology, 2016, 99, 332-350.	4.4	220
25	Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncology, The, 2016, 17, 896-906.	10.7	205
26	Ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 159-179.	4.4	186
27	The cancer survival gap between elderly and middle-aged patients in Europe is widening. European Journal of Cancer, 2009, 45, 1006-1016.	2.8	186
28	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiology, 2014, 38, 670-678.	1.9	174
29	Cancer prevalence in European registry areas. Annals of Oncology, 2002, 13, 840-865.	1.2	164
30	Breast carcinoma survival in Europe and the United States. Cancer, 2004, 100, 715-722.	4.1	163
31	Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 2012, 48, 3257-3266.	2.8	158
32	Glioblastoma in adults. Critical Reviews in Oncology/Hematology, 2008, 67, 139-152.	4.4	156
33	Ependymoma. Critical Reviews in Oncology/Hematology, 2007, 63, 81-89.	4.4	147
34	Adult acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2004, 50, 197-222.	4.4	144
35	Cholangiocarcinoma. Critical Reviews in Oncology/Hematology, 2009, 69, 259-270.	4.4	144
36	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89â€`828 children from 198 registries in 53 countries. Lancet Haematology,the, 2017, 4, e202-e217.	4.6	141

#	Article	IF	CITATIONS
37	Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: Results from EUROCARE-5. European Journal of Cancer, 2015, 51, 2144-2157.	2.8	138
38	Variation in survival of patients with lung cancer in Europe, 1985–1989. European Journal of Cancer, 1998, 34, 2191-2196.	2.8	135
39	The prognostic role of gender in survival of adult cancer patients. European Journal of Cancer, 1998, 34, 2271-2278.	2.8	135
40	Cancer survival increases in Europe, but international differences remain wide. European Journal of Cancer, 2001, 37, 1659-1667.	2.8	135
41	Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer, 1998, 34, 2176-2183.	2.8	133
42	Survival trends in European cancer patients diagnosed from 1988 to 1999. European Journal of Cancer, 2009, 45, 1042-1066.	2.8	133
43	Incidence and survival of rare urogenital cancers in Europe. European Journal of Cancer, 2012, 48, 456-464.	2.8	132
44	Mucosal melanoma of the head and neck. Critical Reviews in Oncology/Hematology, 2017, 112, 136-152.	4.4	125
45	Comparative cancer survival information in Europe. European Journal of Cancer, 2009, 45, 901-908.	2.8	123
46	Socio-economic inequalities: A review of methodological issues and the relationships with cancer survival. Critical Reviews in Oncology/Hematology, 2013, 85, 266-277.	4.4	123
47	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. American Journal of Gastroenterology, 2007, 102, 1661-1670.	0.4	121
48	Survival from rare cancer in adults: a population-based study. Lancet Oncology, The, 2006, 7, 132-140.	10.7	120
49	The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. European Journal of Cancer, 2009, 45, 909-930.	2.8	120
50	Childhood cancer survival in Europe. Annals of Oncology, 2003, 14, v119-v127.	1.2	119
51	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2016, 105, 35-51.	4.4	119
52	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: Results of EUROCARE-5. European Journal of Cancer, 2015, 51, 2169-2178.	2.8	115
53	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut, 2005, 54, 268-273.	12.1	114
54	Survival of patients with oesophageal and gastric cancers in Europe. European Journal of Cancer, 1998, 34, 2167-2175.	2.8	110

#	Article	IF	CITATIONS
55	Multiple tumours in survival estimates. European Journal of Cancer, 2009, 45, 1080-1094.	2.8	109
56	Central nervous system gliomas. Critical Reviews in Oncology/Hematology, 2017, 113, 213-234.	4.4	109
57	Oesophageal cancer survival in Europe: A EUROCARE-4 study. Cancer Epidemiology, 2012, 36, 505-512.	1.9	108
58	Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. European Journal of Cancer, 2003, 39, 2214-2222.	2.8	107
59	Comparison of stomach cancer incidence and survival in four continents. European Journal of Cancer, 2003, 39, 1603-1609.	2.8	102
60	Neuroblastoma (Peripheral neuroblastic tumours). Critical Reviews in Oncology/Hematology, 2016, 107, 163-181.	4.4	101
61	Survival of children with bone sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 760-766.	2.8	99
62	Cancer of the larynx. Critical Reviews in Oncology/Hematology, 2003, 47, 65-80.	4.4	98
63	The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	2.8	97
64	Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. European Journal of Cancer, 1998, 34, 2154-2161.	2.8	96
65	Cholangiocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 116, 11-31.	4.4	96
66	Survival in Patients With Uveal Melanoma in Europe. JAMA Ophthalmology, 2008, 126, 1413.	2.4	95
67	Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncology, 2009, 45, 669-674.	1.5	94
68	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecologic Oncology, 2017, 144, 396-404.	1.4	93
69	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic Oncology, 2017, 144, 405-413.	1.4	93
70	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer, 2013, 49, 2565-2578.	2.8	91
71	Cancer of the prostate. Critical Reviews in Oncology/Hematology, 2005, 56, 379-396.	4.4	89
72	Measuring cancer prevalence in Europe: the EUROPREVAL Project. Annals of Oncology, 2002, 13, 831-839.	1.2	88

#	Article	IF	CITATIONS
73	Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncológica, 2012, 51, 441-453.	1.8	88
74	Long-term survival expectations of cancer patients in Europe in 2000–2002. European Journal of Cancer, 2009, 45, 1028-1041.	2.8	87
75	Cancer survival in European adolescents and young adults. European Journal of Cancer, 2003, 39, 2600-2610.	2.8	84
76	Cancer of the penis. Critical Reviews in Oncology/Hematology, 2005, 53, 165-177.	4.4	82
77	Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. European Journal of Cancer, 2015, 51, 2206-2216.	2.8	82
78	The cure of cancer: A European perspective. European Journal of Cancer, 2009, 45, 1067-1079.	2.8	80
79	Adult acute lymphoblastic leukaemia. Critical Reviews in Oncology/Hematology, 2004, 50, 223-261.	4.4	79
80	Primary central nervous system lymphoma. Critical Reviews in Oncology/Hematology, 2017, 113, 97-110.	4.4	79
81	Germ cell tumours of the testis. Critical Reviews in Oncology/Hematology, 2005, 53, 141-164.	4.4	77
82	Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Annals of Oncology, 2014, 25, 2251-2260.	1.2	77
83	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Annals of Oncology, 2015, 26, 300-306.	1.2	77
84	Survival of European women with gynaecological tumours, during the period 1978–1989. European Journal of Cancer, 1998, 34, 2218-2225.	2.8	76
85	Explaining gastric cancer survival differences among European countries. International Journal of Cancer, 2004, 109, 737-741.	5.1	75
86	Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. European Journal of Cancer, 2015, 51, 2217-2230.	2.8	75
87	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Annals of Oncology, 2003, 14, v14-v27.	1.2	74
88	Gastric cancer. Critical Reviews in Oncology/Hematology, 2005, 54, 209-241.	4.4	73
89	Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open, 2013, 3, e003055.	1.9	72
90	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. European Journal of Cancer, 2017, 77, 140-152.	2.8	72

#	Article	IF	CITATIONS
91	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. European Journal of Cancer, 2012, 48, 1167-1175.	2.8	71
92	Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. International Journal of Cancer, 2013, 132, 2404-2412.	5.1	69
93	Anaplastic astrocytoma in adults. Critical Reviews in Oncology/Hematology, 2007, 63, 72-80.	4.4	67
94	Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study. European Journal of Cancer, 2015, 51, 2120-2129.	2.8	66
95	Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data. Annals of Oncology, 2015, 26, 1263-1268.	1.2	65
96	Comparisons of colon–cancer survival among european countries: The eurocare study. International Journal of Cancer, 1995, 63, 43-48.	5.1	64
97	Hodgkin disease survival in Europe and the U.S Cancer, 2006, 107, 352-360.	4.1	64
98	Oligodendroglioma. Critical Reviews in Oncology/Hematology, 2008, 66, 262-272.	4.4	64
99	Survival of European patients with central nervous system tumors. International Journal of Cancer, 2012, 131, 173-185.	5.1	64
100	Invasive extramammary Paget's disease and the risk for secondary tumours in Europe. European Journal of Surgical Oncology, 2012, 38, 214-221.	1.0	63
101	Childhood melanoma in Europe since 1978. European Journal of Cancer, 2001, 37, 780-784.	2.8	62
102	The EUROCARE II study. European Journal of Cancer, 1998, 34, 2139-2153.	2.8	61
103	Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare CancersAin cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. European Journal of Cancer, 2019, 110, 120-126.	2.8	61
104	Patterns of care for European colorectal cancer patients diagnosed 1996–1998: A EUROCARE High Resolution Study. Acta Oncológica, 2010, 49, 776-783.	1.8	58
105	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2011, 79, 65-83.	4.4	58
106	European disparities in malignant digestive endocrine tumours survival. International Journal of Cancer, 2010, 126, 2928-2934.	5.1	57
107	Survival of children with soft-tissue sarcoma in Europe since 1978. European Journal of Cancer, 2001, 37, 767-774.	2.8	56
108	Incidence of and survival from Wilms' tumour in adults in Europe: Data from the EUROCARE study. European Journal of Cancer, 2006, 42, 2363-2368.	2.8	56

Семма Сатта

#	Article	IF	CITATIONS
109	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Critical Reviews in Oncology/Hematology, 2009, 71, 165-179.	4.4	56
110	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. Lancet Oncology, The, 2016, 17, e163-e172.	10.7	56
111	Survival and age at diagnosis of breast cancer in a population-based cancer registry. European Journal of Cancer & Clinical Oncology, 1991, 27, 981-984.	0.7	55
112	Rare cancers of the head and neck area in Europe. European Journal of Cancer, 2012, 48, 783-796.	2.8	55
113	Cancer prevalence in Central Europe: the EUROPREVAL Study. Annals of Oncology, 2003, 14, 313-322.	1.2	54
114	Variations in survival from breast cancer in Europe by age and country, 1978–1989. European Journal of Cancer, 1998, 34, 2204-2211.	2.8	52
115	The Burden of Rare Cancers in Europe. Advances in Experimental Medicine and Biology, 2010, 686, 285-303.	1.6	52
116	Cancer of the nasopharynx. Critical Reviews in Oncology/Hematology, 2003, 45, 199-214.	4.4	50
117	Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992. European Journal of Cancer, 2001, 37, 711-721.	2.8	47
118	Epidemiology of rare cancers and inequalities in oncologic outcomes. European Journal of Surgical Oncology, 2019, 45, 3-11.	1.0	47
119	Breast cancer incidence and prevalence estimated from survival and mortality. Cancer Causes and Control, 1990, 1, 23-29.	1.8	45
120	Childhood cancer survival in Europe. European Journal of Cancer, 2001, 37, 810-816.	2.8	43
121	Variation in survival of adult patients with thyroid cancer in Europe. European Journal of Cancer, 1998, 34, 2248-2252.	2.8	42
122	Childhood cancer survival in Europe, 1978–1992. European Journal of Cancer, 2001, 37, 671-672.	2.8	42
123	Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995–2002. European Journal of Cancer, 2012, 48, 1417-1424.	2.8	42
124	Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987. European Journal of Cancer, 1996, 32, 831-835.	2.8	41
125	Paranasal sinus cancer. Critical Reviews in Oncology/Hematology, 2016, 98, 45-61.	4.4	41
126	Variation in survival of adult patients with haematological malignancies in Europe since 1978. European Journal of Cancer, 1998, 34, 2253-2263.	2.8	40

Семма Сатта

#	Article	IF	CITATIONS
127	Human Papillomavirus in HNSCC: A European Epidemiologic Perspective. Hematology/Oncology Clinics of North America, 2008, 22, 1143-1153.	2.2	40
128	Embryonal cancers in Europe. European Journal of Cancer, 2012, 48, 1425-1433.	2.8	39
129	Variations in Cancer Survival and Patterns of Care Across Europe: Roles of Wealth and Health-Care Organization. Journal of the National Cancer Institute Monographs, 2013, 2013, 79-87.	2.1	38
130	Survival of adult patients with cancer of soft tissues or bone in Europe. European Journal of Cancer, 1998, 34, 2212-2217.	2.8	37
131	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. European Journal of Cancer, 2012, 48, 159-169.	2.8	37
132	Cancer prevalence estimates in Europe at the beginning of 2000. Annals of Oncology, 2013, 24, 1660-1666.	1.2	36
133	Occupational exposures and colorectal cancers: A quantitative overview of epidemiological evidence. World Journal of Gastroenterology, 2014, 20, 12431.	3.3	36
134	Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study. Annals of Oncology, 2011, 22, 165-174.	1.2	35
135	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	3.5	35
136	Improved survival for patients with testicular cancer in Europe since 1978. European Journal of Cancer, 1998, 34, 2236-2240.	2.8	34
137	Veno-occlusive disease with multi-organ involvement following actinomycin-D. European Journal of Cancer, 2001, 37, 1141-1148.	2.8	34
138	Survival rates for primary malignant brain tumours in Europe. European Journal of Cancer, 1998, 34, 2241-2247.	2.8	33
139	The EUROCARE study of survival of cancer patients in Europe. European Journal of Cancer, 2001, 37, 673-677.	2.8	33
140	Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978–1992. European Journal of Cancer, 2001, 37, 687-694.	2.8	33
141	Childhood malignancies in the EUROCARE study. European Journal of Cancer, 2001, 37, 678-686.	2.8	33
142	Renal cancer. Critical Reviews in Oncology/Hematology, 2007, 64, 247-262.	4.4	33
143	Geographical variability in survival of European children with central nervous system tumours. European Journal of Cancer, 2017, 82, 137-148.	2.8	33
144	Time trends of lung and larynx cancers in Italy. International Journal of Cancer, 1994, 57, 154-161.	5.1	32

#	Article	IF	CITATIONS
145	Lower incidence rates but thicker melanomas in Eastern Europe before 1992. European Journal of Cancer, 2004, 40, 1045-1052.	2.8	32
146	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European Journal of Cancer, 2008, 44, 579-587.	2.8	32
147	Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSC) protocols. Pediatric Blood and Cancer, 2017, 64, e26348.	1.5	32
148	Is the cancer survival improvement in European and American adolescent and young adults still lagging behind that in children?. Pediatric Blood and Cancer, 2019, 66, e27407.	1.5	32
149	Survival of childhood lymphomas in Europe, 1978–1992. European Journal of Cancer, 2001, 37, 703-710.	2.8	31
150	Survival for retinoblastoma in Europe. European Journal of Cancer, 2001, 37, 730-735.	2.8	30
151	A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Annals of Oncology, 2002, 13, 1128-1139.	1.2	30
152	Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study. Cancer Epidemiology, 2018, 56, 146-153.	1.9	30
153	Estimation and projections of colorectal cancer trends in Italy. International Journal of Epidemiology, 1997, 26, 924-932.	1.9	29
154	Colon cancer. Critical Reviews in Oncology/Hematology, 2004, 51, 145-170.	4.4	29
155	Trends in cervical cancer survival in Europe, 1983–1994: A population-based study. Gynecologic Oncology, 2007, 105, 609-619.	1.4	29
156	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: AÂEUROCARE-5 study. European Journal of Cancer, 2017, 84, 335-353.	2.8	29
157	Electronic availability of EUROCARE-3 data: a tool for further analysis. Annals of Oncology, 2003, 14, v150-v155.	1.2	28
158	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. Journal of the National Cancer Institute Monographs, 2013, 2013, 124-130.	2.1	28
159	Variation in survival for adults with Nasopharyngeal cancer in Europe, 1978–1989. European Journal of Cancer, 1998, 34, 2162-2166.	2.8	27
160	Treatment challenges in and outside a network setting: Soft tissue sarcomas. European Journal of Surgical Oncology, 2019, 45, 31-39.	1.0	27
161	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	1.0	27
162	A system for classifying cancers diagnosed in adolescents and young adults. Cancer, 2020, 126, 4634-4659.	4.1	25

#	Article	IF	CITATIONS
163	Prognosis and cureÂof longâ€ŧerm cancer survivors: A populationâ€based estimation. Cancer Medicine, 2019, 8, 4497-4507.	2.8	24
164	Estimation and projections of stomach cancer trends in Italy. Cancer Causes and Control, 1995, 6, 339-346.	1.8	23
165	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Annals of Oncology, 2004, 15, 1136-1142.	1.2	22
166	Survival for ethmoid sinus adenocarcinoma in European populations. Acta Oncológica, 2009, 48, 992-998.	1.8	22
167	Methodological aspects of estimating rare cancer prevalence in Europe: The experience of the RARECARE project. Cancer Epidemiology, 2013, 37, 850-856.	1.9	21
168	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Annals of Oncology, 2015, 26, 838-847.	1.2	21
169	Improving survival of melanoma patients in Europe since 1978. European Journal of Cancer, 1998, 34, 2197-2203.	2.8	20
170	An estimate of the number of people in Italy living after a childhood cancer. International Journal of Cancer, 2017, 140, 2444-2450.	5.1	20
171	Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S24-S31.	1.3	20
172	Cancer of pancreas. Critical Reviews in Oncology/Hematology, 2004, 50, 147-155.	4.4	19
173	Cancer prevalence in Northern Europe: the EUROPREVAL study. Annals of Oncology, 2003, 14, 946-957.	1.2	18
174	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	3.1	18
175	Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. European Journal of Cancer, 2016, 67, 91-98.	2.8	17
176	Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978. European Journal of Cancer, 2001, 37, 695-702.	2.8	16
177	Changes in life expectancy for cancer patients over time since diagnosis. Journal of Advanced Research, 2019, 20, 153-159.	9.5	16
178	Survival for lung cancer in northern Italy. Cancer Causes and Control, 1992, 3, 223-230.	1.8	15
179	Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S63-S69.	1.3	15
180	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. European Journal of Surgical Oncology, 2019, 45, 75-80.	1.0	15

#	Article	IF	CITATIONS
181	Survival of children with Wilms' tumour in Europe. European Journal of Cancer, 2001, 37, 736-743.	2.8	14
182	Rectal cancer. Critical Reviews in Oncology/Hematology, 2009, 70, 160-182.	4.4	14
183	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S48-S55.	1.3	14
184	Survival of children with thyroid cancer in Europe 1978–1989. European Journal of Cancer, 2001, 37, 775-779.	2.8	13
185	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S77-S84.	1.3	13
186	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. Frontiers in Oncology, 2019, 9, 837.	2.8	13
187	Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study. Journal of Cancer Survivorship, 2007, 1, 247-254.	2.9	12
188	The European study on centralisation of childhood cancer treatment. European Journal of Cancer, 2019, 115, 120-127.	2.8	12
189	Prostate cancer treatment in Europe at the end of 1990s. Acta Oncológica, 2009, 48, 867-873.	1.8	11
190	Bayesian estimates of the incidence of rare cancers in Europe. Cancer Epidemiology, 2018, 54, 95-100.	1.9	11
191	Specialized teams or specialist networks for rare cancers?. European Journal of Surgical Oncology, 2015, 41, 1115-1117.	1.0	10
192	Estimates of prostate cancer burden in Italy. Cancer Epidemiology, 2016, 40, 166-172.	1.9	10
193	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S107-S113.	1.3	10
194	Rare cancers in childhood and adolescence in Brazil: First report of data from 19 populationâ€based cancer registries. Cancer, 2019, 125, 2638-2646.	4.1	10
195	Improvement in survival of patients with cancer of the kidney in Europe. European Journal of Cancer, 1998, 34, 2232-2235.	2.8	9
196	Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S70-S76.	1.3	9
197	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S85-S91.	1.3	9
198	Rare cancers: A network for better care. European Journal of Surgical Oncology, 2019, 45, 1-2.	1.0	9

#	Article	IF	CITATIONS
199	Rectal cancer. Critical Reviews in Oncology/Hematology, 2004, 51, 121-143.	4.4	8
200	Cancer survival in Europe, 1999–2007: Doing better, feeling worse?. European Journal of Cancer, 2015, 51, 2101-2103.	2.8	8
201	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. European Journal of Cancer Prevention, 2017, 26, S9-S15.	1.3	7
202	Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S40-S47.	1.3	7
203	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S16-S23.	1.3	7
204	Letter to the editor. International Journal of Cancer, 1989, 44, 186-187.	5.1	6
205	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2019, 20, e652-e660.	2.6	6
206	Incidence of rare cancers in the city of São Paulo, Brazil. Tumori, 2019, 105, 22-30.	1.1	6
207	The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori, 2012, 98, 550-8.	1.1	6
208	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S92-S99.	1.3	5
209	Survival of children with liver tumours in Europe 1978–1989. European Journal of Cancer, 2001, 37, 744-749.	2.8	4
210	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S114-S120.	1.3	4
211	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S32-S39.	1.3	4
212	Excess risk of dying of other causes of cured cancer patients. Tumori, 2019, 105, 199-204.	1.1	4
213	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. European Journal of Surgical Oncology, 2019, 45, 60-66.	1.0	4
214	Cancer survival differences between European populations: the UK uneasiness. British Journal of Cancer, 2001, 85, 785-786.	6.4	3
215	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S56-S62.	1.3	3
216	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S121-S127.	1.3	3

#	Article	IF	CITATIONS
217	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. European Journal of Cancer Prevention, 2017, 26, S3-S8.	1.3	3
218	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	1.0	3
219	Childhood cancer and environmental integrity: a commentary and a proposal. Revista De Saude Publica, 2017, 51, 29.	1.7	2
220	Survival for colorectal cancer Reply. Gut, 2001, 48, 868-869.	12.1	1
221	Changes in Mortality and Incidence of Prostate Cancer by Risk Class in Different Periods in Italy: The Possible Effects of PSA Spread. Tumori, 2017, 103, 292-298.	1.1	1
222	Cancer Survival in Europe and the United States. , 2006, , 112-122.		1
223	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S100-S106.	1.3	0
224	Integrating population data in a computerized Decision Support System for Head and Neck Cancer. , 2019, , .		0
225	Cancer rehabilitation services: an Italian population-based cohort study. Tumori, 2014, 100, 346-51.	1.1	0